Neoeriocitrin
Based on 1 Customer Validation
Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 13241-32-2
- Formula: C27H32O15
- Molecular Weight:596.53
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
|
AChE |
Neoeriocitrin (2-20 μg/mL; 72 h) modulates MC3T3-E1 cell proliferation in a dose-dependent manner[1].
Neoeriocitrin (2-20 μg/mL; 5 days) increases MC3T3-E1 cell ALP activity in a dose-dependent manner[1].
Neoeriocitrin (2 μg/mL; 4-8 days) upregulates expression of osteogenic marker genes Runx2, COL I, and OCN in MC3T3-E1 cells[1].
Neoeriocitrin (2 μg/mL; 5 days) partially rescues PD98059 (HY-12028)-induced inhibition of ALP activity in MC3T3-E1 cells[1].
Neoeriocitrin (2 μg/mL; 4-8 days) partially rescues PD98059-induced downregulation of COL I and OCN mRNA expression in MC3T3-E1 cells[1].
Neoeriocitrin (2.5-200 μM; 1-14 days) significantly and sustainably promotes the proliferation of human dental pulp stem cells[2].
Neoeriocitrin (2.5-10 μM; 7-21 days) enhances the osteogenic differentiation of human dental pulp stem cells, as measured by increased osteogenic gene and protein expression, alkaline phosphatase activity, and mineralization[2].
Neoeriocitrin (100 μM; 1 h) directly binds to Beclin1 in human dental pulp stem cells, as identified by increased thermal stability of Beclin1 in thermal proteome profiling[2].
Neoeriocitrin (2.5-10 μM; 48 h) induces autophagy in human dental pulp stem cells, as measured by reduced P62 levels, increased LC3-II/I ratio, enhanced autophagosome formation, and increased autophagosome number detected via transmission electron microscopy[2].
Neoeriocitrin (5 μM) requires Beclin1 as a critical mediator for its induced autophagy and osteogenic differentiation in human dental pulp stem cells, as Beclin1 knockdown attenuates and Beclin1 overexpression amplifies Neoeriocitrin's effects[2].
Neoeriocitrin (5 μM; 3-12 h) stabilizes Beclin1 protein in human dental pulp stem cells by inhibiting ubiquitin-mediated proteasomal degradation, thereby extending Beclin1 half-life[2].
Neoeriocitrin (6×104 μM; 2 h pre-incubation, 22 h co-incubation with Aβ25-35) protects Aβ25-35 (HY-P0128)-damaged PC12 cells by reducing apoptosis, upregulating ERβ expression, inhibiting P38 protein phosphorylation, and improving cholinergic system function[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MC3T3-E1 preosteoblast cells
-
Concentration:2, 4, 8, 10, 20 μg/mL
-
Incubation Time:72 h
-
Result:Increased proliferation rate at 2 and 4 μg/mL.
Decreased proliferation rate at 8-10 μg/mL.
-
Cell Line:MC3T3-E1 preosteoblast cells
-
Concentration:2 μg/mL
-
Incubation Time:4 days (Runx2 and COL I); 8 days (OCN)
-
Result:Increased Runx2, COL I and OCN mRNA expression.
-
Cell Line:human dental pulp stem cells (hDPSCs)
-
Concentration:.5, 5, 10,
25, 50, 100, and 200 μM -
Incubation Time:, 3, 5, 7, and 14 days
-
Result:Produced a sustained, significant enhancement of hDPSCs proliferation from day 5 onwards at 2.5, 5, and 10 μM, compared to control or higher concentrations.
Stimulated proliferation in the first 3 days at concentrations below 200 μM.
-
Cell Line:human dental pulp stem cells (hDPSCs)
-
Concentration:2.5,
5, and 10 μM -
Incubation Time:7 days (ALP staining, gene/protein expression); 21 days (alizarin red staining)
-
Result:Most significantly upregulated osteogenesis-related mRNA (Collagen I, ALP, OPN, Runx2) and protein (Collagen I, ALP, OPN, Runx2) expression.
Showed the largest positive area percentage in ALP staining at 7 days with 5 μM.
Showed the highest mineralization in alizarin red staining at 21 days with 5 μM.
-
Cell Line:human dental pulp stem cells (hDPSCs)
-
Concentration:2.5,
5, and 10 μM -
Incubation Time:48 h
-
Result:Significantly reduced P62 protein levels and increased the LC3-II/I ratio at 2.5 and 5 μM.
Showed a diminished, non-significant effect on P62 at 10 μM.
Increased the number of yellow (RFP+GFP+) puncta (autophagosomes) and the number of autophagosomes visible via TEM at 5 μM, compared to control.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 13241-32-2
-
Appearance Solid
-
Molecular Weight 596.53
-
Formula C27H32O15
-
Color White to off-white
-
SMILES
O=C1C2=C(O)C=C(O[C@H]3[C@@H]([C@H]([C@H](O)[C@@H](CO)O3)O)O[C@@]4([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O4)O)O)C=C2O[C@H](C5=CC(O)=C(O)C=C5)C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL (167.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li L, et al. Comparison of neoeriocitrin and naringin on proliferation and osteogenic differentiation in MC3T3-E1. Phytomedicine. 2011;18(11):985-989. [Content Brief]
[2]. Wu Y, et al. Neoeriocitrin Targeting Beclin1 Deubiquitination and Autophagy in Osteogenic Differentiation of Human Dental Pulp Stem Cells. Adv Sci (Weinh). 2025;12(43):e04378. [Content Brief]
[4]. van der Meer JW, et al. Abstract!. Neth J Med. 2002;60(11):418. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6764 mL | 8.3818 mL | 16.7636 mL | 41.9090 mL |
| 5 mM | 0.3353 mL | 1.6764 mL | 3.3527 mL | 8.3818 mL | |
| 10 mM | 0.1676 mL | 0.8382 mL | 1.6764 mL | 4.1909 mL | |
| 15 mM | 0.1118 mL | 0.5588 mL | 1.1176 mL | 2.7939 mL | |
| 20 mM | 0.0838 mL | 0.4191 mL | 0.8382 mL | 2.0955 mL | |
| 25 mM | 0.0671 mL | 0.3353 mL | 0.6705 mL | 1.6764 mL | |
| 30 mM | 0.0559 mL | 0.2794 mL | 0.5588 mL | 1.3970 mL | |
| 40 mM | 0.0419 mL | 0.2095 mL | 0.4191 mL | 1.0477 mL | |
| 50 mM | 0.0335 mL | 0.1676 mL | 0.3353 mL | 0.8382 mL | |
| 60 mM | 0.0279 mL | 0.1397 mL | 0.2794 mL | 0.6985 mL | |
| 80 mM | 0.0210 mL | 0.1048 mL | 0.2095 mL | 0.5239 mL | |
| 100 mM | 0.0168 mL | 0.0838 mL | 0.1676 mL | 0.4191 mL |